For the quarter ending 2025-12-31, ARWR had -$25,011K decrease in cash & cash equivalents over the period. $11,333K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net income (loss) | 28,242 | 16,121 | 13,993 |
| Stock-based compensation | 19,371 | 19,087 | 44,279 |
| Depreciation and amortization | 6,390 | 6,386 | 17,542 |
| Non-cash gain on treasury stock received | - | 3,193 | - |
| Accretion of note premiums/discounts | 1,215 | 1,244 | 4,545 |
| Realized gain on investments | 19 | 0 | 0 |
| Non-cash interest expense on liability related to the sale of future royalties | 7,600 | 26,036 | 18,893 |
| Non-cash interest expense on credit facility | 14,905 | 14,551 | 48,774 |
| Accounts receivable | 212,046 | 47,126 | 9,841 |
| Inventory | 451 | - | - |
| Prepaid expenses and other current assets | 13,182 | -12,403 | 22,342 |
| Accounts payable | 15,263 | -15,376 | 21,662 |
| Accrued expenses | -13,501 | 33,541 | 7,956 |
| Deferred revenue | 163,359 | -20,580 | 22,979 |
| Operating lease, net | -1,211 | -1,188 | -3,417 |
| Other | 24 | 34 | -3,128 |
| Net cash provided by (used in) operating activities | 13,481 | 20,491 | 159,061 |
| Purchases of property, plant and equipment | 2,148 | 7,489 | 15,177 |
| Purchases of investments | 136,933 | 21,642 | 774,616 |
| Proceeds from sales and maturities of investments | 115,339 | 101,750 | 587,880 |
| Net cash (used in) provided by investing activities | -23,742 | 72,619 | -201,913 |
| Repayments of credit facility | - | - | 201,625 |
| Proceeds from the exercises of stock options | 5,098 | 507 | 3,476 |
| Proceeds from visirna credit agreement | - | 3,162 | 7,098 |
| Proceeds from the sale of future royalties | - | 0 | 0 |
| Proceeds from the issuance of pre-funded warrants | 0 | 0 | 25,000 |
| Payments of debt issuance costs | 0 | 0 | 5,000 |
| Proceeds from the issuance of common stock, net of issuance costs paid | 46,832 | 0 | 241,388 |
| Proceeds from credit facility | - | 0 | - |
| Repayments of credit facility | 66,680 | 201,625 | - |
| Net cash (used in) provided by financing activities | -14,750 | 3,669 | 70,337 |
| Net decrease in cash, cash equivalents and restricted cash | -25,011 | 96,779 | 27,485 |
| Effect of exchange rate changes on cash | 106 | -401 | - |
| Cash and cash equivalents at beginning of period | 226,548 | 102,685 | - |
| Cash and cash equivalents at end of period | 201,643 | 226,548 | - |
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)